Beta blockers proven effective through clinical trials (bisoprolol, carvedilol, or sustained-release metoprolol succinate) are recommended for all hemodynamically stable patients without documented contraindications (Class I, Level A). It is particularly important to titrate these agents slowly into the “green zone” where the risk benefit ratio supports use of these agents.